About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/28/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/28/2021.

Targeting Attention Orienting to Social Threat to Reduce Social Anxiety in Youth

Clinicaltrials.gov identifier NCT03932032

Recruitment Status Active, not recruiting

First Posted April 30, 2019

Last update posted April 10, 2020

Study Description

Brief summary:

This two-site study is a test of Attention Bias Modification Treatment (ABMT) among 260 youths ages 10 to 14 years with social anxiety disorder. One-half of participants will receive 8 sessions of computer administered ABMT and the other half of participants will receive 8 sessions of computer administered Neutral Control Task (NCT). The investigators hypothesize that a biomarker of attention to social threat measured using electroencephalography (EEG) and ratings of social anxiety severity will be lower in participants who receive ABMT compared to participants who receive NCT.

  • Condition or Disease:Social Anxiety Disorder of Childhood
  • Intervention/Treatment: Behavioral: Attention Bias Modification Treatment
    Behavioral: Neutral Control Task
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 260 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: Targeting Attention Orienting to Social Threat to Reduce Social Anxiety in Youth
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: March 2024
  • Estimated Study Completion Date: March 2024
Arms and interventions
Arm Intervention/treatment
Experimental: Attention Bias Modification Treatment
Attention Bias Modification Treatment is a computer-based attention training program.
Behavioral: Attention Bias Modification Treatment
At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
Sham Comparator: Neutral Control Task
Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
Behavioral: Neutral Control Task
At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
Outcome Measures
  • Primary Outcome Measures: 1. P1 amplitude elicited in the dot-probe task [ Time Frame: post-intervention (within one week of completing the final treatment session) ]
    Posttreatment event related potential amplitude elicited during the emotional faces dot probe task. The investigators will focus specifically on the P1 amplitude time-locked to the onset of facial stimuli in the dot probe task. P1 amplitude will be measured using EEG methodology.
  • 2. P1 amplitude elicited in the dot-probe task [ Time Frame: Follow-up (six months after completing the final treatment session) ]
    Follow-up P1 event related potential amplitude elicited during the emotional faces dot probe task. The investigators will focus specifically on the P1 amplitude time-locked to the onset of facial stimuli in the dot probe task. P1 amplitude will be measured using EEG methodology.
  • Secondary Outcome Measures: 1. Liebowitz Social Anxiety Scale for Children and Adolescents [ Time Frame: post-intervention (within one week of completing the final treatment session) ]
    posttreatment clinician rating of youth social anxiety symptom severity over the past 7 days. The name of the measure is the Liebowitz Social Anxiety Scale for Children and Adolescents. It is a clinician rated measure of the severity of youths' social anxiety symptoms. Total scores range from 0 to 144, with higher scores representing more severe social anxiety.
  • 2. Liebowitz Social Anxiety Scale for Children and Adolescents [ Time Frame: Follow-up (six months after completing the final treatment session) ]
    Follow-up clinician rating of youth social anxiety symptom severity over the past 7 days. The name of the measure is the Liebowitz Social Anxiety Scale for Children and Adolescents. It is a clinician rated measure of the severity of youths' social anxiety symptoms. Total scores range from 0 to 144, with higher scores representing more severe social anxiety.
  • 3. Screen for Child Anxiety Related Emotional Disorders - Parent Version at posttreatment [ Time Frame: 7 days ]
    posttreatment parent rating of youth social anxiety symptom severity over the past 7 days. The name of the measure is the Screen for Child Anxiety Related Emotional Disorders - Parent Version (SCARED-P). The SCARED-P is a parent rated measure of the severity of youths' anxiety symptoms, including social anxiety. Total scores on the SCARED-P range from 0 to 82, with higher scores representing more severe anxiety.
  • 4. Screen for Child Anxiety Related Emotional Disorders - Parent Version at Follow up [ Time Frame: 7 days ]
    follow up parent rating of youth social anxiety symptom severity over the past 7 days. The name of the measure is the Screen for Child Anxiety Related Emotional Disorders - Parent Version (SCARED-P). The SCARED-P is a parent rated measure of the severity of youths' anxiety symptoms, including social anxiety. Total scores on the SCARED-P range from 0 to 82, with higher scores representing more severe anxiety.
  • 5. Screen for Child Anxiety Related Emotional Disorders - Child Version at posttreatment [ Time Frame: 7 days ]
    posttreatment child rating of youth social anxiety symptom severity over the past 7 days. The name of the measure is the Screen for Child Anxiety Related Emotional Disorders - Child Version (SCARED-C). The SCARED-C is a child rated measure of the severity of youths' anxiety symptoms, including social anxiety. Total scores on the SCARED-C range from 0 to 82, with higher scores representing more severe anxiety.
  • 6. Screen for Child Anxiety Related Emotional Disorders - Child Version at Follow-Up [ Time Frame: 7 days ]
    Follow up child rating of youth social anxiety symptom severity over the past 7 days. The name of the measure is the Screen for Child Anxiety Related Emotional Disorders - Child Version (SCARED-C). The SCARED-C is a child rated measure of the severity of youths' anxiety symptoms, including social anxiety. Total scores on the SCARED-C range from 0 to 82, with higher scores representing more severe anxiety.
  • Other Outcome Measures: 1. State Anxiety before and after a Speech Task [ Time Frame: post-intervention (within one week of completing the final treatment session) ]
    posttreatment State-Trait Anxiety Inventory for Children - State Subscale (STAIC-S) administered before and after a 3-minute speech task.
  • 2. State Anxiety before and after a Speech Task [ Time Frame: Follow-up (six months after completing the final treatment session) ]
    Follow-up State-Trait Anxiety Inventory for Children - State Subscale (STAIC-S) administered before and after a 3-minute speech task.
Eligibility Criteria
  • Ages Eligible for Study: 10 to 14 Years (Child)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Be between ages 10 and 14 years

- meet DSM5 criteria for a diagnosis of Social Anxiety Disorder

- presence of any coexisting psychiatric diagnoses must be of lesser severity than
Social Anxiety Disorder

- have no current psychotropic medication other than a stable dose of stimulant or
non-stimulant medication for coexisting ADHD

Exclusion Criteria:

- meet DSM5 criteria for Autism Spectrum Disorder, Intellectual Disability, Bipolar
Disorder, Tourette's Disorder, Psychotic Disorders, or Substance Use Disorders

- show high likelihood of hurting self or others

- be a victim of undisclosed abuse requiring investigation/ supervision by the
Department of Social Services

- have an uncorrected vision or physical disability that interferes with the ability to
click a mouse button rapidly and repeatedly

- have a history of neurological illness, including seizures/epilepsy, or head injury
with loss of consciousness > 5 minutes

Contacts and Locations
Contacts
Locations

United States, Connecticut
Yale Child Study Center Program for Anxiety and Mood Disorders
New Haven

United States, Florida
Florida International University Center for Children and Families
Miami

Sponsors and Collaborators

Florida International University

Yale University

Investigators

Principal Investigator: Jeremy W Pettit, PhD Florida International University

Principal Investigator: Wendy K Silverman, PhD Yale University

More Information
  • Responsible Party: Florida International University
  • ClinicalTrials.gov Identifier: NCT03932032 History of Changes
  • Other Study ID Numbers: R01MH119299
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: April 10, 2020
  • Last Verified: April 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Phobia, Social Anxiety Disorders